Using electroacupuncture to prevent nausea and vomiting in breast cancer patients undergoing chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III trial evaluates the effectiveness of electroacupuncture combined with standard antiemetic drugs in preventing nausea and vomiting in breast cancer patients receiving highly emetogenic chemotherapy. Participants will be randomly assigned to receive either electroacupuncture or sham acupuncture alongside olanzapine and other antiemetic medications. The study will also investigate the potential relationship between genetic factors and the effectiveness of electroacupuncture. Outcomes will include the frequency of nausea and vomiting, use of rescue medications, and any adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 years or older and aged 75 years or younger, of any nationality;
2. Eastern Cooperative Oncology Group performance status of 0-2;
3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)/cisplatin;
4. Predicted life expectancy of ≥3 months;
5. Adequate bone marrow, kidney, and liver function;
6. Adequate contraception if premenopausal women;
7. Written informed consent by the patient before enrolment.

Exclusion Criteria:

1. Patients already submitted to chemotherapy;
2. Is scheduled to receive any non-HEC on Day 1;
3. Is scheduled to receive any chemotherapy on days 2-4 after HEC;
4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;
5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting;
6. Have ongoing emesis or CTCAE grade 2 or greater nausea;
7. Significant medical or mental conditions;
8. Any allergies to study drug, antiemetics or dexamethasone;
9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine);
10. Patients who are pregnant or breast-feeding;
11. Inflammatory skin reaction;
12. Has lymphedema in acupuncture stimulation area;
13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles;
14. Received acupuncture treatments for any conditions less than 4 weeks before HEC;
15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation));
16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis;
17. Has a convulsive disorder requiring anticonvulsant treatment;
18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment);
19. Concurrent treatment with quinolone antibiotics;
20. Has a history of chronic alcoholism (determined by the investigator);
21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months;
22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).

Where it's running

• Qinghai University Affiliated Hospital
  Xining, Qinghai, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining electroacupuncture with antiemetic therapy for nausea in breast cancer patients

  This study is testing if combining electroacupuncture with standard anti-nausea medication can help breast cancer patients feel less sick during chemotherapy.

  Recruiting Phase 3 Lanzhou University Second Hospital · Lanzhou, Gansu · NCT06314906

• Sedation with dexmedetomidine, propofol, or both during cataract surgery

  This project will test whether dexmedetomidine, propofol, or their combination (each given with fentanyl) provides the best sedation, safety, and surgeon satisfaction for adults having cataract surgery.

  Recruiting Saint-Joseph University · Beirut · NCT07556133

• Tradipitant for GLP-1R agonist–related nausea and vomiting in adults with overweight or class I–II obesity

  This trial will test if tradipitant can reduce nausea and vomiting caused by GLP-1 receptor agonist weight-loss medicines in adults who are overweight or have class I–II obesity.

  Recruiting at 3 sites Phase 3 Vanda Pharmaceuticals · Los Angeles, California and 9 other locations · NCT07446439

• Electroacupuncture plus PD‑1 immunotherapy for advanced non‑small cell lung cancer with ECOG 2

  This trial will see if adding electroacupuncture to PD‑1 immunotherapy helps people with advanced non‑small cell lung cancer who have an ECOG performance status of 2.

  Recruiting First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, Tianjin Municipality · NCT07239661

• Electroacupuncture plus PD-1 immunotherapy for older adults with advanced non-small cell lung cancer

  It will test whether adding electroacupuncture to PD‑1 immunotherapy helps people aged 65 and older with advanced non‑small cell lung cancer live longer, feel better, or have fewer side effects.

  Recruiting First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, Tianjin Municipality · NCT07086300

• Zusanli (ST36) electroacupuncture plus immunotherapy in NSCLC before surgery

  This trial tests whether adding electroacupuncture at ST36 to standard neoadjuvant immunotherapy helps patients with NSCLC better respond to treatment.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07076836

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.